Article Text

Download PDFPDF
Thromboembolism peaking 3 months after starting testosterone therapy: testosterone–thrombophilia interactions
  1. Charles J Glueck,
  2. Naila Goldenberg,
  3. Ping Wang
  1. Lipoprotein Metabolism, Thrombosis Research Center, Cincinnati, Ohio, USA
  1. Correspondence to Dr Charles J Glueck, Lipoprotein Metabolism, Thrombosis Research Center, Cincinnati, Ohio, 45220, USA; sonar16{at}


We assessed time of thrombotic events (venous thromboembolism (VTE)) after starting testosterone therapy (TT) in 21 men who sustained 23 VTE. The density of thrombotic events was greatest at 3 months after starting TT, with a rapid decline in events by 10 months. The 21 cases with VTE on TT differed from 110 patient controls with unprovoked VTE, not taking TT (VTE-no TT) for Factor V Leiden heterozygosity (FVL) (33 per cent vs 13 per cent, P=0.037), for high lipoprotein (a) (Lp(a)) (55 per cent vs 17 per cent, P=0.012), and for the lupus anticoagulant (33 per cent vs 4 per cent, P=0.003). These differences between cases and VTE-no TT controls were independent of age and gender. TT can interact with underlying thrombophilia–hypofibrinolysis promoting VTE. We suggest that TT should not be started in subjects with known thrombophilia. Coagulation screening, particularly for the FVL , Lp(a), and the lupus anticoagulant should be considered before starting TT, to identify men at high VTE risk who have an adverse risk/benefit ratio for TT.

  • testosterone
  • thrombophilia
  • thromboembolism
  • thrombosis
  • pulmonary embolism

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Contributors All authors did data collection, writing and data editing. CJG and PW did statistics.

  • Funding The study was supported by the lipoprotein reseach fund of the Jewish Hospital of Cincinnati.

  • Competing interests None declared.

  • Ethics approval Institutional review board of the Jewish Hospital of Cincinnati.

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Data sharing statement Additional unpublished data from the study could be obtained from ping wang PhD